Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
for Symptomatic Hypertrophic Cardiomyopathy (HCM)
Drug: Aficamten
52 locations incl. Birmingham
Sponsor: Cytokinetics
Sex: All·Age: 18 - 85
Code: NCT04848506·Phase 2, Phase 3·Enrolling By Invitation